Hormonal
GLP-1 receptor agonists (GLP-1 RAs) improve glycemic control and promote weight loss in patients with type 2 diabetes and obesity through mechanisms including enhanced glucose-dependent insulin secretion, suppressed glucagon release, delayed gastric emptying, and central appetite suppression.
GLP-1 receptor agonists are highly effective medications for managing type 2 diabetes and obesity. They work by mimicking a natural hormone to increase insulin when needed, suppress glucagon, slow down digestion, and reduce appetite. This leads to significant weight loss and better blood sugar control with a lower risk of hypoglycemia compared to older diabetes drugs. Common side effects like nausea are usually temporary and can be managed by starting with a low dose and increasing it gradually. Both injectable and oral options exist, making them accessible for many patients.
GLP-1 RAs mimic the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety.
Why this rating
The paper cites multiple clinical trials (e.g., LEADER, SUSTAIN-6, SURPASS) and meta-analyses, though it is a review chapter rather than a single primary trial.
Source
New and Interesting Benefits with New Molecules in Obesity and Type 2 Diabetes
Fernando Grover Páez et al. · IntechOpen eBooks · 2026
DOI 10.5772/intechopen.1009256
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →